Albany Molecular Research Cash from Financing Quarterly:
-0.227M for Dec. 31, 2012Albany Molecular Research Historical Cash from Financing Quarterly Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | -0.227M |
| Sept. 30, 2012 | 0.189M |
| June 30, 2012 | 2.177M |
| March 31, 2012 | -4.673M |
| Dec. 31, 2011 | -3.524M |
| Sept. 30, 2011 | -0.113M |
| June 30, 2011 | 2.096M |
| March 31, 2011 | -5.428M |
| Dec. 31, 2010 | 0.016M |
| Sept. 30, 2010 | -9.606M |
| June 30, 2010 | -0.342M |
| March 31, 2010 | 0.254M |
| Dec. 31, 2009 | 0.001M |
| Sept. 30, 2009 | 0.217M |
| June 30, 2009 | -0.155M |
| March 31, 2009 | 0.192M |
| Dec. 31, 2008 | -3.473M |
| Sept. 30, 2008 | 1.135M |
| June 30, 2008 | -3.442M |
| March 31, 2008 | Go Pro |
| Dec. 31, 2007 | Go Pro |
| Sept. 30, 2007 | Go Pro |
| June 30, 2007 | Go Pro |
| March 31, 2007 | Go Pro |
| Dec. 31, 2006 | Go Pro |
| Sept. 30, 2006 | Go Pro |
| June 30, 2006 | Go Pro |
| March 31, 2006 | Go Pro |
| Dec. 31, 2005 | Go Pro |
| Sept. 30, 2005 | Go Pro |
| June 30, 2005 | Go Pro |
| March 31, 2005 | Go Pro |
| Dec. 31, 2004 | Go Pro |
| Sept. 30, 2004 | Go Pro |
| June 30, 2004 | Go Pro |
| March 31, 2004 | Go Pro |
| Dec. 31, 2003 | Go Pro |
| Sept. 30, 2003 | Go Pro |
| June 30, 2003 | Go Pro |
| March 31, 2003 | Go Pro |
| Dec. 31, 2002 | Go Pro |
| Sept. 30, 2002 | Go Pro |
| June 30, 2002 | Go Pro |
| March 31, 2002 | Go Pro |
| Dec. 31, 2001 | Go Pro |
| Sept. 30, 2001 | Go Pro |
| June 30, 2001 | Go Pro |
| March 31, 2001 | Go Pro |
| Dec. 31, 2000 | Go Pro |
| Sept. 30, 2000 | Go Pro |
About Cash From Financing
An item on a company's cash flow statement. Lists aggregate change in cash position resulting from financing activities. Includes the company's cash inflows and outflows from issuing cash dividends, issuing and selling stock, and adding or changing loans.
Learn More
AMRI Cash from Financing Quarterly Benchmarks
| Companies | |
|---|---|
| Cambrex Corporation | 9.317M |
| Achillion Pharmaceuticals | 133.23M |
| Anacor Pharmaceuticals | 20.53M |
AMRI Cash from Financing Quarterly Rankings
| Overall |
68th percentile 2514 of 8002 |
| Sector |
40th percentile 410 of 684 in Healthcare |
| Industry |
29th percentile 175 of 248 in Biotechnology |
AMRI Cash from Financing Quarterly Range, Past 5 Years
| Minimum | -9.606M | Sep 2010 |
| Maximum | 2.177M | Jun 2012 |
| Average | -1.300M |
